The Experts below are selected from a list of 4470 Experts worldwide ranked by ideXlab platform

Wei Liu - One of the best experts on this subject based on the ideXlab platform.

  • Supraclavicular Lymph Node dissection with radiotherapy versus radiotherapy alone for operable breast cancer with synchronous ipsilateral Supraclavicular Lymph Node metastases a real world cohort study
    Gland surgery, 2020
    Co-Authors: Minghao Wang, Wei Liu, Lingmi Hou, Xiao-dong Zheng, Yuting Jin, Yuzhao Yan, Qinwen Pan, Xuanni Tan, Yuan Tian, Yi Zhang
    Abstract:

    Background The role of Supraclavicular Lymph Node dissection (SCLD) in the treatment of breast cancer with ipsilateral Supraclavicular Lymph Node metastasis (ISLM) remains controversial. We evaluated the role of SCLD in the treatment of breast cancer with ISLM and identified patients who may benefit from SCLD. Methods Data on patients presenting with breast cancer to the Breast Disease Center, Southwest Hospital, The Army Medical University from January 2004 and December 2017 were retrospectively screened. The median duration of follow-up was 36 months (2-175 months). 305 patients who were recently diagnosed with ISLM were eligible for the analysis. Results Overall, 9,236 women presented with breast cancer during the study period. Among the patients included, 146 and 159 received SCLD with radiotherapy (RT) and RT alone, respectively. Synchronous ISLM without distant metastases were present in 3.6% cases. The 3- and 5-year overall survival (OS) and disease-free survival (DFS) rates were 79.5% and 73.9%, respectively, and 67.5% and 54.8%, respectively. However, SCLD with RT was not associated with superior survival on both univariate and multivariate analyses. On stratified analyses, patients with non-luminal A tumors with 4-9 positive axillary Lymph Nodes who underwent SCLD with RT had both superior OS (HR =5.296; 95% CI: 1.857-15.107; P=0.001) and DFS (HR =5.331; 95% CI: 2.348-12.108; P<0.001) compared with those who received RT alone. Conclusions SCLD may not beneficial in improving survival for unselected breast cancer patients with ISLNM. There is less of a tendency to perform SCLD in the luminal A group.

  • Supraclavicular Lymph Node dissection with radiotherapy versus radiotherapy alone for operable breast cancer with synchronous ipsilateral Supraclavicular Lymph Node metastases: a real-world cohort study
    Gland surgery, 2020
    Co-Authors: Minghao Wang, Lingmi Hou, Xiao-dong Zheng, Yan Yuzhao, Pan Qinwen, Yuting Jin, Wei Liu
    Abstract:

    Background The role of Supraclavicular Lymph Node dissection (SCLD) in the treatment of breast cancer with ipsilateral Supraclavicular Lymph Node metastasis (ISLM) remains controversial. We evaluated the role of SCLD in the treatment of breast cancer with ISLM and identified patients who may benefit from SCLD. Methods Data on patients presenting with breast cancer to the Breast Disease Center, Southwest Hospital, The Army Medical University from January 2004 and December 2017 were retrospectively screened. The median duration of follow-up was 36 months (2-175 months). 305 patients who were recently diagnosed with ISLM were eligible for the analysis. Results Overall, 9,236 women presented with breast cancer during the study period. Among the patients included, 146 and 159 received SCLD with radiotherapy (RT) and RT alone, respectively. Synchronous ISLM without distant metastases were present in 3.6% cases. The 3- and 5-year overall survival (OS) and disease-free survival (DFS) rates were 79.5% and 73.9%, respectively, and 67.5% and 54.8%, respectively. However, SCLD with RT was not associated with superior survival on both univariate and multivariate analyses. On stratified analyses, patients with non-luminal A tumors with 4-9 positive axillary Lymph Nodes who underwent SCLD with RT had both superior OS (HR =5.296; 95% CI: 1.857-15.107; P=0.001) and DFS (HR =5.331; 95% CI: 2.348-12.108; P

  • Misdiagnosis of left Supraclavicular Lymph Node metastasis of hepatocellular carcinoma: a case report.
    World journal of gastroenterology, 2013
    Co-Authors: Tao Liu, Jun-fang Gao, Hai Ding, Wei Liu
    Abstract:

    Left Supraclavicular Lymph Node metastasis is a rare presentation of hepatocellular carcinoma (HCC). This phenomenon is easily neglected in the clinic. A 56-year-old man presented with HCC. On examination, a 1cm long left Supraclavicular Lymph Node was palpated. Auxiliary examination indicated a lesion located in the right lobe of the liver. Fine needle aspiration cytology (FNAC) of the enlarged Lymph Node was performed; however, only necrosis was found. Hepatectomy was performed and HCC was confirmed by Hematoxylin-Eosin staining. However, 14 d after surgery, significantly enlarged left Supraclavicular Lymph Nodes, a new intrahepatic lesion, and pulmonary and mediastinal metastasis appeared. An excisional biopsy of the left Supraclavicular Lymph Node was performed, and its findings confirmed metastatic HCC. The patient’s HCC rapidly progressed and he died one month later. It is possible for HCC to metastasize to the left Supraclavicular Lymph Node. Surgeons should always consider an overall physical examination. When left Supraclavicular Lymphadenopathy of unknown origin is encountered, FNAC should be performed initially. If the results are negative, an excisional biopsy and subsequent Positron emission tomography - computed tomography scanning should be performed. These are very important for making the correct diagnosis and for selecting reasonable therapies.

Mijin Yun - One of the best experts on this subject based on the ideXlab platform.

Su-wei Chen - One of the best experts on this subject based on the ideXlab platform.

Na Luo - One of the best experts on this subject based on the ideXlab platform.

  • surgery of the primary tumor offers survival benefits of breast cancer with synchronous ipsilateral Supraclavicular Lymph Node metastasis
    World Journal of Surgery, 2020
    Co-Authors: Q. Chen, Piao Zhao, Qiongyan Zou, Dengjie Ouyang, Liyun Zeng, Lei Pei, Na Luo
    Abstract:

    Controversy exists around the locoregional management of the primary tumor for breast cancer associated with synchronous ipsilateral Supraclavicular Lymph Node metastasis (sISLM) due to the rarity of the disease and limited available data. This study aimed to compare outcomes of patients in the Surveillance, Epidemiology, and End Results (SEER) database with sISLM who underwent surgical resection and radiation of the primary tumor with those who did not. This population-based retrospective study included breast cancer patients with sISLM without distant metastases from 2004 to 2016 in the SEER database. In this study, patients had been stratified by operative management, and propensity score matching (PSM) had been successfully applied. A total of 1172 breast cancer patients with sISLM were included in the study: 863 (73.6%) of patients underwent the primary tumor resection, and 309 (26.4%) patients did not undergo surgery. The median survival time in the surgery group was longer compared to the nonsurgery group in the overall cohort and the PSM cohort. We concluded that the primary tumor resection was associated with improved survival. Subgroup analysis further demonstrated that local surgery was not inferior to radical surgery. For selected breast cancer patients with sISLM, surgery is a promising local intervention which may improve the survival.

Suk Hyun Lee - One of the best experts on this subject based on the ideXlab platform.